{"transactions":[{"id":2061556,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:00:33.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":115000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-23-001759","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919123001759/doc4.xml","form_type":"4"}},{"id":2440958,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T22:00:33.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":118750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":118750,"derivative":{"exercise_price":3.24,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":118750},"source":{"system":"sec-edgar","filing":"0001209191-22-002212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919122002212/doc4.xml","form_type":"4"}},{"id":2913220,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-07T21:00:13.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":100000,"derivative":{"exercise_price":13,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-002477","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121002477/doc4.xml","form_type":"4"}},{"id":2992092,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C-1 Preferred Stock","published_at":"2020-11-05T01:00:20.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":1441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3746},"source":{"system":"sec-edgar","filing":"0000899243-20-030415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030415/doc4.xml","form_type":"4"}},{"id":2992091,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-05T01:00:20.000Z","date":"2020-10-07","kind":"grant","acquired":true,"shares":77991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":77991,"derivative":{"exercise_price":7.7,"expiration_date":"2030-10-06","underlying":"Common Stock","underlying_shares":77991},"source":{"system":"sec-edgar","filing":"0000899243-20-030415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030415/doc4.xml","form_type":"4"}},{"id":2992090,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-05T01:00:20.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":142983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":142983,"derivative":{"exercise_price":1.95,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":142983},"source":{"system":"sec-edgar","filing":"0000899243-20-030415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030415/doc4.xml","form_type":"4"}},{"id":2992089,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120900,"kind":"person","name":"Pedersen Anders","position":1,"cik":"0001825779","reported_name":"Pedersen Anders","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:00:20.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":3746,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date."}],"balance_after":3746,"source":{"system":"sec-edgar","filing":"0000899243-20-030415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000089924320030415/doc4.xml","form_type":"4"}}]}